Loading
Harbinger Health's study of whether its blood tests can help sort out which people with worrying symptoms have cancer.
PROCARES (NCT07046260) is an observational study sponsored by Harbinger Health. Its primary objective is to establish the performance of two blood-based diagnostic-aid tests for cancer detection in people presenting with symptoms, signs or findings suggestive of cancer.
The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 2,450 participants, a start on 11 July 2025 and primary completion expected in November 2026.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/